Rui Wang1,2, Yi-Xuan Yin1, Qaisar Mahmood1, Xiao-Juan Wang1, Yin-Ping Gao1, Guo-Jing Gou3, Muhammad Masood Ahmed1, Fukunag Kohji4, Yong-Zhong Du1, Feng Han1. 1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. 2. Department of Pharmacology, Key Laboratory of Ministry of Education in Fertility Preservation and Maintenance, Ningxia Medical University, Yinchuan, China. 3. Department of Medical Chemistry, Ningxia Medical University, Yinchuan, China. 4. Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan.
Abstract
AIMS: Vascular dementia (VaD) is a heterogeneous brain disorder for which there are no effective approved pharmacological treatments available. We aimed to evaluate the effect of calmodulin inhibitor, DY-9836, and its loaded nanodrug carrier system on cognitive impairment and gain a better understanding of the protective mechanisms in mice with bilateral carotid artery stenosis (BCAS). RESULTS: DY-9836 (0.5 or 1 mg/kg) or DY-9836 (0.25 mg/kg)-encapsulated polysialic acid-octadecylamine (PSA-ODA) micelles (PSA-ODA/DY) were given to BCAS mice for 4 weeks. Administration of DY-9836 or PSA-ODA/DY reduced escape latency in space exploration and working memory test compared with vehicle group. Vehicle-treated mice showed reduced phospho-CaMKII (Thr286/287) levels in the hippocampus, whereas partially restored by DY-9836 (1 mg/kg) or PSA-ODA/DY (0.25 mg/kg) treatment. In accordance with the pharmacological profile of DY-9836 observed during behavioral studies, experimental molecular and biochemical markers induced by BCAS, such as protein tyrosine nitration, Nod-like receptor protein 3 (NLRP3), caspase-1, and interleukin-1β, were reduced by DY-9836 and PSA-ODA/DY treatment. CONCLUSIONS: These data disclose novel findings about the therapeutic potential of DY-9836, and its encapsulated nanodrug delivery system significantly enhanced the cognitive function via inhibitory effect on nitrosative stress and NLRP3 signaling in VaD mice.
AIMS: Vascular dementia (VaD) is a heterogeneous brain disorder for which there are no effective approved pharmacological treatments available. We aimed to evaluate the effect of calmodulin inhibitor, DY-9836, and its loaded nanodrug carrier system on cognitive impairment and gain a better understanding of the protective mechanisms in mice with bilateral carotid artery stenosis (BCAS). RESULTS:DY-9836 (0.5 or 1 mg/kg) or DY-9836 (0.25 mg/kg)-encapsulated polysialic acid-octadecylamine (PSA-ODA) micelles (PSA-ODA/DY) were given to BCAS mice for 4 weeks. Administration of DY-9836 or PSA-ODA/DY reduced escape latency in space exploration and working memory test compared with vehicle group. Vehicle-treated mice showed reduced phospho-CaMKII (Thr286/287) levels in the hippocampus, whereas partially restored by DY-9836 (1 mg/kg) or PSA-ODA/DY (0.25 mg/kg) treatment. In accordance with the pharmacological profile of DY-9836 observed during behavioral studies, experimental molecular and biochemical markers induced by BCAS, such as protein tyrosine nitration, Nod-like receptor protein 3 (NLRP3), caspase-1, and interleukin-1β, were reduced by DY-9836 and PSA-ODA/DY treatment. CONCLUSIONS: These data disclose novel findings about the therapeutic potential of DY-9836, and its encapsulated nanodrug delivery system significantly enhanced the cognitive function via inhibitory effect on nitrosative stress and NLRP3 signaling in VaD mice.
Authors: Ype Elgersma; Nikolai B Fedorov; Sami Ikonen; Esther S Choi; Minetta Elgersma; Ofelia M Carvalho; Karl Peter Giese; Alcino J Silva Journal: Neuron Date: 2002-10-24 Impact factor: 17.173
Authors: A Lobo; L J Launer; L Fratiglioni; K Andersen; A Di Carlo; M M Breteler; J R Copeland; J F Dartigues; C Jagger; J Martinez-Lage; H Soininen; A Hofman Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: G M S Nys; M J E van Zandvoort; H B van der Worp; E H F de Haan; P L M de Kort; B P W Jansen; L J Kappelle Journal: J Neurol Sci Date: 2006-05-22 Impact factor: 3.181
Authors: John T O'Brien; Timo Erkinjuntti; Barry Reisberg; Gustavo Roman; Tohru Sawada; Leonardo Pantoni; John V Bowler; Clive Ballard; Charles DeCarli; Philip B Gorelick; Kenneth Rockwood; Alistair Burns; Serge Gauthier; Steven T DeKosky Journal: Lancet Neurol Date: 2003-02 Impact factor: 44.182